Transdermal Patch Growth Relying on Improved Designs, Enhanced Manufacturing Methods - Future Demand Linked to Patient Acceptance

Main Category: Pharma Industry / Biotech Industry
Also Included In: Dermatology
Article Date: 06 Sep 2007 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


As competition among prescription drugs escalates, driven in part by direct-to-consumer advertising, the role of combination products in meeting market expectations and extending patent life is increasing. Drug products for which alternative delivery methods exist are highly susceptible to patient and caregiver perceptions. Since a significant interest in transdermal drug delivery patches is based on the perception that patches are more convenient, ease-of-use in accessing and applying drug patches is a critical demand factor.

Shire's recent partial withdrawal of some Daytrana ADHD patches because of feedback from patients and caregivers who have experienced difficulty removing the release liner from patches underscores the need for players in this segment to not only measure and analyze user issues during the patch product clinical trial process, but to continue to monitor patient acceptance after market launch. In response to the Daytrana feedback, the company is using an enhanced process to offer patients and caregivers improved ease of use when peeling the release liner off the patches.

The market leaders in patch design and manufacturing, a select group that includes 3M and Noven, are addressing patient concerns by developing patches that are smaller and more esthetic. Extending patch technology to new drug classes and therapeutic targets will require further enhancements to address dosing issues and patient-to-patient variability.

More information is available at http://www.greystoneassociates.org/Skin_Patches.htm.

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

http://www.greystoneassociates.org

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Greystone. "Transdermal Patch Growth Relying on Improved Designs, Enhanced Manufacturing Methods - Future Demand Linked to Patient Acceptance." Medical News Today. MediLexicon, Intl., 6 Sep. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/81519.php>

APA
Greystone. (2007, September 6). "Transdermal Patch Growth Relying on Improved Designs, Enhanced Manufacturing Methods - Future Demand Linked to Patient Acceptance." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/81519.php.

Please note: If no author information is provided, the source is cited instead.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »